Navigation Links
Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
Date:1/4/2008

FRAZER, Pa., Jan. 4 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that Frank Baldino, Jr., Ph.D., Chairman and CEO will present at the JP Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, CA. Dr. Baldino will deliver a one hour presentation on Tuesday, January 8, 2008 beginning at 2:00 p.m. Pacific Time (11 a.m. Eastern Time).

Live Web Cast and Archived Replay

Members of the financial and investment community, the media and other interested parties can access a live web cast of the presentation through the investor relations section of the company's website http://www.cephalon.com. Following the live presentation, a replay of the presentation will be available for two weeks on the company's website.

About Cephalon, Inc.

Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
2. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
3. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
4. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
5. DaVita Inc. to Present at JPMorgan Healthcare Conference
6. Hologic to Present at the 26th Annual JP Morgan Healthcare Conference
7. WebMD to Present at Upcoming Investor Conferences
8. Neurochem to present at JPMorgan Healthcare Conference
9. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
10. MedCath Corporation to Present at the 26th Annual JPMorgan Healthcare Conference
11. Insulet Corporation to Present at the JPMorgan Healthcare Conference on January 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... 30, 2017 , ... The Aresty Institute of Executive Education ... to address the increasingly complex educational needs of today's global executives. Corporate ... corporate finance and will increase their ability to confidently take action in ways ...
(Date:3/30/2017)... ... 30, 2017 , ... Nutrition Education for the Public (NEP), ... join nonprofit Seafood Nutrition Partnership (SNP) in presenting “Eating Heart Healthy: Exploring Issues ... educators and students inform consumers about the health benefits of eating a seafood-rich ...
(Date:3/29/2017)... ... , ... During the last week of March, Chad Kawa, MD of Revere ... the local community. , Colon cancer is the second leading cause of cancer ... it is small, confined and easier to treat. If you are 50 or older, ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... women’s professional squash, announced it has enlisted New York City-based sports and entertainment ... will develop and procure sponsorship opportunities for the Professional Squash Association (PSA), which ...
(Date:3/29/2017)... Baltimore, MD (PRWEB) , ... March 30, 2017 , ... ... , Charm City Run has announced that Mercy Medical Center will serve as the ... in the Mid-Atlantic region. On Sunday, June 25, 2017, thousands of women will walk ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the ... 2025" report to their offering. ... The global orthopedic navigation ... 2025. Increasing geriatric population prone to orthopedic diseases is a ... over the forecast period. Osteoarthritis and osteoporosis are most common ...
(Date:3/29/2017)... , March 29, 2017  Experts in the ... monitoring devices like  Soberlink Systems  as a model ... paper, published in early 2017, concluded that remote ... in managing patient recovery." The findings ... of Addiction Medicine, detail a range of variables ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, a ... GSP 301, an investigational fixed-dose combination of mometasone ... administered twice-daily as a nasal spray being studied ... results are from a recently completed Phase 3 ... 301 combination therapy versus mometasone, olopatadine or placebo. ...
Breaking Medicine Technology: